In a landmark initiative aimed at curbing the spread of one of the most widespread sexually transmitted infections, the UK’s National Health Service (NHS) has launched the world’s first national vaccination programme against gonorrhoea. The campaign, currently underway in sexual health clinics across England, targets individuals most vulnerable to the infection.
The programme utilizes the 4CMenB vaccine, known commercially as Bexsero®, which was initially developed to guard against meningitis B. However, recent studies have revealed it offers partial protection against gonorrhoea, a closely related bacterial disease. The rollout represents a significant leap in the fight against STIs globally.
Initially, the vaccine will be offered to gay, bisexual, and other men who have sex with men (GBMSM), particularly those who have had multiple partners or were diagnosed with a bacterial STI in the past year. Additional high-risk groups may also be included as the programme expands.
The move comes in response to a sharp increase in gonorrhoea infections in the UK. In 2023 alone, England recorded over 85,000 cases—three times the figure from ten years ago, and the highest since official records began in 1918.
NHS England’s National Medical Director, Professor Sir Stephen Powis, hailed the vaccination effort as a crucial intervention, particularly as antibiotic resistance continues to limit treatment options.
Projections by Imperial College London estimate that the programme could prevent over 100,000 gonorrhoea cases over the next decade, potentially saving the NHS around £8 million in healthcare costs. While not fully effective, the vaccine has been shown to reduce the risk of infection by up to 40%, a significant impact given the rising resistance to antibiotics.
Dr Mary Ramsay, head of immunization at the UK Health Security Agency, said the scientific evidence supporting the initiative is compelling. She noted that even a moderate level of protection could bring meaningful public health benefits.
This vaccination drive is part of a broader preventative health strategy under the UK government’s “Plan for Change.” During appointments, eligible patients may also be offered additional vaccines, including those for mpox, HPV, and hepatitis A and B.
The national expansion is expected by September 2025, with sexual health clinics leading the effort to identify and reach eligible individuals. As the first country to implement such a programme, the UK is being closely watched by health authorities worldwide, many of whom see it as a timely and necessary response to a growing public health threat.
“This marks a global turning point in STI prevention,” said Steve Russell, NHS Director of Vaccination and Screening. “We’re hopeful other nations will take similar action.” The NHS is now encouraging those who may qualify to visit their local sexual health clinic for more information.